Echographie en gynécologie bovine, ovine et caprine, réalisation d'un CD-Rom didactique

L'échographie est un outil de diagnostic à l'innocuité avérée, fiable et précoce, couramment utilisé par les vétérinaires chez les ruminants et très bien accepté par les éleveurs qui y ont vu la supériorité d'un tel moyen d'investigation. Notre travail a consisté à concevoir et à réaliser un CD-Rom de gynécologie des ruminants, à visée didactique pour les vétérinaires et les techniciens intervenant en reproduction. Les différentes situations classiquement rencontrées en gynécologie bovine (examen des ovaires, diagnostic de gestation, contrôle d'involution utérine), ovine (diagnostic de gestation et dénombrement) et caprine (diagnostic de gestation et détection de pseudogestations) sont illustrées par des images échographiques, des photographies, des schémas et des films. Ce CD-Rom est un outil dynamique qui se veut pédagogique pour les praticiens ou les étudiants vétérinaires et doit permettre à son utilisateur d'améliorer son aptitude à réaliser et interpréter des images échographiques.MAISONS-ALFORT-Ecole Vétérin (940462302) / SudocSudocFranceF

Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial.

International audienceThe overall quality of life of patients with rectal cancer is quite good 4.6 years after the beginning preoperative treatments. However, adding chemotherapy to preoperative radiotherapy has a negative effect on diarrhoea complaints and some quality of life dimensions

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

Background: A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen deprivation therapy (ADT) should be maintained when CRPC develops and when treatment with any of the newer agents is initiated. Aim: However, to emphasise this recommendation, it is valuable to interrogate the evidence for maintaining ADT in different clinical situations. Outcome: This statement, reflecting the views of the authors, provides a discussion of this evidence and the rationale behind the recommendation that ADT should be continued in CRPC.SCOPUS: re.jinfo:eu-repo/semantics/publishe

A systematic review of economic evaluation in pancreatic ductal adenocarcinoma

International audienceObjectives: The economic evaluation (EE) of healthcare interventions has become a necessity. However, high quality needs to be ensured in order to achieve validated results and help making informed decisions. Thus, the objective of the present study was to systematically identify and review published pancreatic ductal adenocarcinoma-related EEs and to assess their quality. Methods: Systematic literature research was conducted in PubMed and Cochrane to identify published EEs between 2000 and 2015. The quality of each selected EE was assessed by two independent reviewers, using the Drummond's checklist. Results: Our systematic review was based on 32 EEs and showed a wide variety of methodo-logical approaches, including different perspectives, time horizon, and cost effectiveness analyses. Nearly two-thirds of EEs are full EEs (n Z 21), and about one-third of EEs had a Drummond score 7, synonymous with 'high quality'. Close to 50% of full EEs had a Drum-mond score 7, whereas all of partial EEs had a Drummond score <7 (n Z 11). Conclusions: Over the past 15 years, a lot of interest has been evinced over the EE of pancre-atic ductal adenocarcinoma (PDAC) and its direct impact on therapeutic advances in PDAC. To provide a framework for health care decision-making, to facilitate transferability and to lend credibility to health EEs, their quality must be improved. For the last 4 years, a tendency towards a quality improvement of these studies has been observed, probably coupled with a context of rational decision-making in health care, a better and wider spread of recommendations and thus, medical practitioners' full endorsement.

A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient (case report).

International audienc

Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

International audiencePURPOSE: In 1996, we initiated the French multicenter phase III randomized trial to compare the effect on disease-free survival (DFS) of concurrent versus sequential chemotherapy (CT) and radiotherapy (RT) after breast-conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow-up of 60 months. PATIENTS AND METHODS: Between February 1996 and April 2000, 716 patients were entered onto this trial. Adjuvant treatment began within 6 weeks after surgery. Sequential treatment of CT administered first followed by RT was compared with concurrent treatment of CT administered with RT. The CT regimen consisted of mitoxantrone (12 mg/m2), fluorouracil (500 mg/m2), and cyclophosphamide (500 mg/m2) on day 1, and it was repeated every 21 days for six courses. RT was delivered to the breast and, when indicated, to the regional lymphatics. RESULTS: There was no statistically significant difference in treatment in the 5-year DFS (80% in both groups; P = .83), locoregional recurrence-free survival (LRFS; 92% in sequential v 95% in concurrent; P = .76), metastasis-free survival (87% in sequential v 84% in concurrent; P = .55), or overall survival (90% in sequential v 91% in concurrent; P = .76). Nevertheless, in the node-positive subgroup, the 5-year LRFS was statistically better in the concurrent arm (97% in concurrent v 91% in sequential; P = .02), corresponding to a risk of locoregional recurrence decreased by 39% (hazard ratio, 0.61; 95% CI, 0.38 to 0.93). CONCLUSION: This treatment protocol remains an appealing clinical option for many women with operable breast cancer at a high risk of recurrence. Combination treatments with new drugs for breast cancer are warranted

Reactivity of ethanol over hydroxyapatite-based Ca-enriched catalysts with various carbonate contents

International audienc